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Central nervous system (CNS) diseases associated with acute leukemia should be discerned from a multitude of disease categories, including invasive collagen disease, infectious 
diseases, drug- or radiotherapy-related leukoencephalopathy, 
and vascular lesions [1]. It is difficult to differentiate several 
potential etiologies based only on the clinical presentation, and 
the definitive diagnosis is usually made by histopathological 
examination. It is important to present negative outcomes 
resulting from a misdiagnosis or delayed diagnosis to improve our 
knowledge in choosing the most appropriate therapeutic strategy. 
Herein, we report the diagnostic considerations and successful 
therapeutic response in a case of acute myelogenous leukemia 
(AML) complicated by a progressive intracranial necrotic lesion.
CASE REPORT
In April 2016, a 52-year-old man experienced right unilateral 
weakness and sensory loss but did not seek medical attention. 
1 month later, he presented at a nearby general hospital 
complaining of progressive weakness and numbness of the right 
upper extremities and face. Cranial magnetic resonance imaging 
(MRI) findings at the time were unremarkable. Orthopedic 
evaluation was performed, and the patient was diagnosed with 
cervical spondylosis and treateSd conservatively. However, no 
improvement in symptoms was seen; therefore, he was admitted 
for further investigations in May.
On admission, neurological examination revealed Japan Coma 
Scale 1 (Glasgow coma scale: 3-5-6), right hemiparesis (manual/
muscle testing: 4-/5), and right hemisensory deficit, including of 
the face. The laboratory results were within normal limits, except 
for a low white blood cell count (1280/µL). His prothrombin 
time was 91.6 s, prothrombin international normalized ratio was 
1.04, and D-dimer level was 1.5 µg/mL. The cerebrospinal fluid 
(CSF) results revealed a cell count of 3/µL (polymorphonuclear 
leukocytes - 0% and monocytes - 100%); protein, 37 mg/dL; and 
glucose, 66 mg/dL. Blood and CSF cultures showed no evidence 
of bacterial, fungal, or viral infection. Contrast MRI showed 
partial enhancement and perifocal edema in the left subcortical 
parietal lobe, and both T1-and T2-weighted images showed low 
intensity (Fig. 1). He was followed up continuously because his 
condition remained unchanged.
In July, the laboratory data again revealed a low white blood 
cell count (1400/µL); therefore, the patient was referred to our 
institute’s Department of Hematology. Bone marrow biopsy 
was performed, which showed a high number of large immature 
and dysfunctional red blood cells (megaloblasts) (62.8%) and 
reductions in granulocytes and neutrophils, leading to the 
diagnosis of leukemia. Subsequently, he was hospitalized for 
further examination and treatment.
Follow-up MRI showed expansion of the left parietal 
subcortical lesion, with increased contrast enhancement and 
edema (Fig. 2). Digital subtraction angiography revealed a slight 
vascular blush in the lesion area. To make a definitive diagnosis, 
a brain biopsy was performed using a pen. The intraoperative 
findings included partial whitish discoloration in the parietal 
gray matter, with several ischemic cortical arteries. Because the 
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lesion was located directly over the motor area, three 1 cm×1 cm 
blocks of discolored whitish cortex in the posterior aspect of the 
superior parietal lobule were removed. The cut surface of the 
parietal resection of the arteries revealed vessel wall thickening; 
moreover, the white-colored tissue with total occlusion of the 
vessel lumen was considered related to tumor growth.
Pathology results using the immunoblot method showed 
liquefactive necrosis, along with inflammatory lymphocytes 
(Fig. 3). There was no pathological evidence of tumor cells or 
any infectious lesion. The precise diagnosis of the intracranial 
lesion was unclear; however, a presumptive etiology secondary 
to AML was considered. On post-operative day 6, standard AML 
chemotherapy treatment was initiated with high-dose cytarabine. 
Steroids were administered at 1 week postoperatively, but the 
patient did not respond to treatment. By hospital day 33, the 
patient showed almost complete resolution of the hemisensory 
deficits and was able to walk without assistance. Contrast MRI 
at that time demonstrated substantial shrinkage of both the lesion 
and perifocal edema. At 1 month postoperatively, the CSF blasts 
were 11.4%; further treatment was determined to be ineffective, 
and a diagnosis of incomplete remission was made.
Therefore, the patient underwent whole brain radiotherapy (2.5 
Gy×2 days) in combination with systemic radiotherapy (3 Gy/4 
Fr×3 days). Bone marrow transplantation could not be performed 
due to lack of an appropriate donor. Instead, an umbilical 
cord transplant was performed to stimulate the production of 
neutrophils. Consequently, complete remission was achieved. 
3 months postoperatively, the patient had recovered, with almost no 
right hemiparesis and sensory deficits. Follow-up MRI at this time 
revealed reduced edema and contrast enhancement (Fig. 4). Written 
informed consent for publication of this report was obtained from 
the patient before surgery. Ethics approval was not sought.
DISCUSSION
The differential diagnoses for CNS diseases associated with 
AML infiltrative collagen diseases, infections, drug treatment 
side effects, and vascular diseases. Consequently, considering the 
grave consequences of misdiagnosis, early and accurate diagnosis 
and treatment are essential [2].
Progressive multifocal leukoencephalopathy (PML) due to John 
Cunningham viral infection is one of the most common infectious 
diseases associated with AML. Characteristic radiological 
features include periventricular and subcortical demyelinating 
plaques on MRI, with unilateral or bilateral asymmetric weakly 
enhancing lesions [3]. In addition, reactivation of herpes simplex 
has been reported to occur in 25–61% of leukemia patients during 
the chemotherapy induction phase [4,5]. In our case, because the 
patient was immunosuppressed, the presence of negative cultures 
ruled out an infectious etiology, despite a high signal on diffusion-
weighted MRI.
Figure 1: Magnetic resonance imaging revealed partial enhancement 
(a) and fluid-attenuated inversion recovery imaging revealed 
perifocal edema of the left subcortical parietal lobe (b)
Figure 2: On the 14th day of admission, cranial magnetic resonance 
imaging showed expansion of the left parietal subcortical lesion, with 
increased contrast enhancement (a) and edema was noted on fluid-
attenuated inversion recovery imaging (b)
Figure 3: Permanent tissue pathology results showed liquefactive 
necrosis, along with a portion that included inflammatory 
lymphocytes
Figure 4: 3 months postoperatively, the patient had recovered, with 
almost no neurological deficits. At that time, follow-up magnetic 
resonance imaging revealed a reduction of the previously observed 
contrast enhancement (a) and edema on fluid-attenuated inversion 
recovery imaging (b)
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Post-methotrexate leukoencephalopathy reportedly accounts 
for the majority of cases of leukemia-related encephalopathy, 
while intracranial radiation accounts for the remaining cases, 
with progression occurring within several months to years [6]. 
Typically, acute disseminating encephalomyelitis is characterized 
by a good response to treatment with steroids, with increased 
CSF cell counts, and mild bilateral cortical enhancement on MRI. 
However, in our case, there was a poor response to steroids, and 
based on the radiological findings and CSF results, this was, 
hence, an unlikely cause.
Regarding PML, although drug-induced etiologies are 
common, because there was only mild enhancement on MRI, 
the findings suggested an atypical form of PML. In addition, 
while there have been reports of cases related to drugs such as 
tacrolimus [7] because the radiological findings for reversible 
posterior leukoencephalopathy usually involve bilateral 
distribution in the occipital and parietal lobes, this was also an 
unlikely cause. Thus, because our case had an unremarkable 
history and no medication history, the likelihood of drug-related 
etiology was ruled out.
Stroke presenting as the first symptom of hematological 
disease has been reported to occur in 1.27–13.5% of all vascular 
diseases; among these, there have been few reports on leukemia. 
Most of the cases of stroke as a complication of leukemia have 
been observed during the treatment phase; these include reports of 
hemorrhagic infarction due to mycotic embolic dissemination and 
agranulocytosis, invasive leukemia cells and massive leukocytosis 
due to multiple intracerebral hemorrhages, and intracerebral 
hemorrhage due to disseminated intravascular coagulation and 
coagulopathies [8]. In our case, though the clinical and radiological 
findings on MRI and digital subtraction angiography were not 
typical for cerebral infarction, the possibility of infarction could 
not be completely ruled out.
Finally, the prognosis of granulocytic sarcoma is closely 
related to the prognosis of AML, with an effective response 
to intensive chemotherapy and local radiotherapy [9]. The 
incidence of granulocytic sarcoma is 2.9–6.8% in myelogenous 
leukemia autopsy cases [10]. Therapy is based on the treatment 
of myelogenous leukemia and comprises mainly chemotherapy; 
however, for cases of granulocytic sarcoma, the prognosis is poor, 
with a reported average survival of only 8 months [11].
Considering the occurrence of AML and the progressive 
enlargement of the lesion, we suspect that the primary pathology 
of our case involves a granulocytic sarcoma or metastatic tumor. 
However, because the pre-operative abdominal, thoracic computed 
tomography was unremarkable and the specific tumor markers were 
negative, the possibility of a metastatic tumor can essentially be 
ruled out. The lack of any evidence of tumor cells on the pathological 
examination may be explained by the need to perform a limited 
resection due to the location of the lesion and the presence of unclear 
borders. In addition, the location of the lesion may have shifted, 
which would have resulted in difficulty performing a resection.
Based on the above, we consider that myeloid sarcoma 
was the most likely diagnosis, because the lesion regressed, 
and the clinical symptoms improved after leukemia treatment. 
However, complete remission was not achieved until whole brain 
radiotherapy in combination with systemic radiotherapy and 
umbilical cord transplant could be performed.
CONCLUSIONS
The differential diagnosis in patients with immunosuppression due to 
the treatment of hematogenous diseases and who have concomitant 
CNS lesions should consider the patient’s clinical condition and 
course. It is necessary to use a combination of radiological and 
laboratory findings to make the diagnosis. Delays in the treatment 
of AML with associated CNS disease, which has a poor prognosis, 
can result in serious sequelae. When the location of the lesion is in 
a critical brain area controlling speech, motor functions, or senses, 
it becomes more difficult to treat brain tumors successfully. The 
present case illustrates the necessity of considering a combination 
of factors to rule out other possible diagnoses; this will permit 
starting appropriate therapy as early as possible.
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